Serum levels of IgG antibodies against oxidized LDL and atherogenic indices in HIV-1-infected patients treated with protease inhibitors

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorCUNHA, Joel da
dc.contributor.authorMASELLI, Luciana Morganti Ferreira
dc.contributor.authorTREITINGER, Aricio
dc.contributor.authorMONTEIRO, Andrea Moreira
dc.contributor.authorGIDLUND, Magnus
dc.contributor.authorMARANHAO, Raul Cavalcanti
dc.contributor.authorSPADA, Celso
dc.contributor.authorBYDLOWSKI, Sergio Paulo
dc.date.accessioned2013-09-23T16:36:08Z
dc.date.available2013-09-23T16:36:08Z
dc.date.issued2013
dc.description.abstractBackground: Antibodies against low-density lipoproteins (LDLs) that have been oxidized are associated with development of atherosclerotic lesions. In individuals infected with human immunodeficiency virus type 1 (HIV-1) with or without therapy, dyslipidemia and increased cardiovascular risk are observed. Methods: Serum levels of IgG antibodies against oxidized LDLs (IgG anti-oxLDL Abs) were determined by assay in 151 HIV-1-infected patients. Of these, 42 patients did not receive anti-retroviral therapy (ART-naive), whereas 109 received highly active anti-retroviral therapy (HAART) consisting of lopinavir/ritonavir (LOP/r; n=50), efavirenz (EFV; n=30) and nevirapine (NVP; n=29) associated with nucleoside reverse transcriptase inhibitors. HIV-1 seronegative individuals (n=43) participated in the study. The following parameters were quantified: total cholesterol and its fractions, atherogenic indices (AIs), apolipoproteins A1 and B100, high sensitivity C-reactive protein, CD4(+) and CD8(+) T cells, and HIV-1-RNA. Results: Levels of IgG anti-oxLDL Abs were significantly higher (p<0.05) in the LOP/r group compared with the EFV and/or NVP and the seronegative group: median 0.32 (0.15, 0.58; 95% confidence interval) vs. 0.25 (0.13, 0.53) vs. 0.18 (0.04, 0.38), respectively. HIV-1-infected ART-naive patients (n=42) presented antibodies levels similar to those observed for the LOP/r group, 0.33 (0.13, 0.63; p>0.05). The levels of IgG anti-oxLDL Abs correlated with an increase in AIs (r=0.216; p=0.036) and triglycerides (r=0.220; p=0.044) in the LOP/r group, and AIs in the ART-naive group (r=0.300; p=0.046). Conclusions: Patients treated with LOP/r showed higher levels of IgG anti-oxLDL Abs compared with patients treated with EFV or NVP regimens, and these levels were associated with an increase in AIs.
dc.description.indexMEDLINE
dc.description.sponsorshipNational Counsel of Technological and Scientific Development (CNPq)
dc.description.sponsorshipState of Sao Paulo Research Foundation (FAPESP)
dc.description.sponsorshipNational Institute of Science and Technology of Complex Fluids (INCT-FCx)
dc.identifier.citationCLINICAL CHEMISTRY AND LABORATORY MEDICINE, v.51, n.2, p.371-378, 2013
dc.identifier.doi10.1515/cclm-2012-0225
dc.identifier.issn1434-6621
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1770
dc.language.isoeng
dc.publisherWALTER DE GRUYTER & CO
dc.relation.ispartofClinical Chemistry and Laboratory Medicine
dc.rightsrestrictedAccess
dc.rights.holderCopyright WALTER DE GRUYTER & CO
dc.subjectatherogenic indices
dc.subjecthighly active anti-retroviral therapy (HAART)
dc.subjectHIV-1
dc.subjectIgG anti-oxidized low-density lipoprotein antibodies
dc.subjectprotease inhibitors
dc.subject.otherlow-density-lipoprotein
dc.subject.otherhiv-infected patients
dc.subject.otherantiretroviral therapy
dc.subject.othermyocardial-infarction
dc.subject.othercardiovascular risk
dc.subject.otheratherosclerosis
dc.subject.othercholesterol
dc.subject.otherefavirenz
dc.subject.otheroxidation
dc.subject.othercohort
dc.subject.wosMedical Laboratory Technology
dc.titleSerum levels of IgG antibodies against oxidized LDL and atherogenic indices in HIV-1-infected patients treated with protease inhibitors
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.author.externalMASELLI, Luciana Morganti Ferreira:Univ Sao Paulo, Med Sch HCFMUSP, Lab Genet & Mol Hematol, Sao Paulo, Brazil; Pro Sangue Fdn Blood Ctr Sao Paulo, Mol Genet & Biotechnol Dept, Div Res, Sao Paulo, Brazil
hcfmusp.author.externalTREITINGER, Aricio:Fed Univ Santa Catarina CCS UFSC, Hlth Sci Ctr, Florianopolis, SC, Brazil
hcfmusp.author.externalMONTEIRO, Andrea Moreira:Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Sao Paulo, Brazil
hcfmusp.author.externalGIDLUND, Magnus:Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Sao Paulo, Brazil
hcfmusp.author.externalSPADA, Celso:Fed Univ Santa Catarina CCS UFSC, Hlth Sci Ctr, Florianopolis, SC, Brazil
hcfmusp.citation.scopus9
hcfmusp.contributor.author-fmusphcJOEL DA CUNHA
hcfmusp.contributor.author-fmusphcRAUL CAVALCANTE MARANHAO
hcfmusp.contributor.author-fmusphcSERGIO PAULO BYDLOWSKI
hcfmusp.description.beginpage371
hcfmusp.description.endpage378
hcfmusp.description.issue2
hcfmusp.description.volume51
hcfmusp.origemWOS
hcfmusp.origem.pubmed23241595
hcfmusp.origem.scopus2-s2.0-84875459331
hcfmusp.origem.wosWOS:000314999000028
hcfmusp.publisher.cityBERLIN
hcfmusp.publisher.countryGERMANY
hcfmusp.relation.referenceBrandao SA, 2010, AM J HYPERTENS, V23, P208, DOI 10.1038/ajh.2009.214
hcfmusp.relation.referenceCASTELLI WP, 1983, CIRCULATION, V67, P730
hcfmusp.relation.referenceChaix C, 2000, J ACQ IMMUN DEF SYND, V24, P227
hcfmusp.relation.referenceChang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699
hcfmusp.relation.referenceChou MY, 2008, J INTERN MED, V263, P479, DOI 10.1111/j.1365-2796.2008.01968.x
hcfmusp.relation.referencede Carvalho EH, 2010, METAB SYNDR RELAT D, V8, P403, DOI 10.1089/met.2009.0092
hcfmusp.relation.referenceDragsted UB, 2003, J INFECT DIS, V188, P635, DOI 10.1086/377288
hcfmusp.relation.referenceDube MP, 2008, CARDIOVASC TOXICOL, V8, P15, DOI 10.1007/s12012-007-9010-y
hcfmusp.relation.referenceEstrada V, 2011, BMC WOMENS HEALTH, V11, DOI 10.1186/1472-6874-11-36
hcfmusp.relation.referenceFaviou E, 2005, FREE RADICAL RES, V39, P419, DOI 10.1080/10715760500072156
hcfmusp.relation.referenceFisac C, 2005, AIDS, V19, P917, DOI 10.1097/01.aids.0000171405.46113.bf
hcfmusp.relation.referenceFRIEDEWA.WT, 1972, CLIN CHEM, V18, P499
hcfmusp.relation.referenceFriis-Moller N, 2003, NEW ENGL J MED, V349, P1993
hcfmusp.relation.referenceGrinspoon S, 2005, NEW ENGL J MED, V352, P48, DOI 10.1056/NEJMra041811
hcfmusp.relation.referenceHui DY, 2003, PROG LIPID RES, V42, P81, DOI 10.1016/S0163-7827(02)00046-2
hcfmusp.relation.referenceItabe H, 2009, CLIN REV ALLERG IMMU, V37, P4, DOI 10.1007/s12016-008-8095-9
hcfmusp.relation.referenceKadar A, 2001, CARDIOVASC SURG, V9, P109, DOI 10.1016/S0967-2109(00)00097-1
hcfmusp.relation.referenceLaczik R, 2011, LUPUS, V20, P730, DOI 10.1177/0961203311398884
hcfmusp.relation.referenceLalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026
hcfmusp.relation.referenceMary-Krause M, 2003, AIDS, V17, P2479, DOI 10.1097/00002030-200311210-00010
hcfmusp.relation.referenceMatsuura E, 2008, AUTOIMMUN REV, V7, P558, DOI 10.1016/j.autrev.2008.04.018
hcfmusp.relation.referenceMedeiros AMB, 2010, ARQ BRAS CARDIOL, V95, P47, DOI 10.1590/S0066-782X2010005000063
hcfmusp.relation.referenceMillán Jesús, 2009, Vasc Health Risk Manag, V5, P757
hcfmusp.relation.referenceNavab M, 2004, J LIPID RES, V45, P993, DOI 10.1194/jlr.R400001-JLR200
hcfmusp.relation.referenceNegredo E, 2004, ANTIVIR THER, V9, P889
hcfmusp.relation.referencePanel on Anti-retroviral Guidelines for Adults and Adolescents, 2009, MMWR RECOMM REP, P1
hcfmusp.relation.referenceParra S, 2010, J INFECT DIS, V201, P627, DOI 10.1086/650312
hcfmusp.relation.referencePereira SA, 2006, BRIT J CLIN PHARMACO, V61, P601, DOI 10.1111/j.1365-2125.2006.02619.x
hcfmusp.relation.referencePetit JM, 2003, J LIPID RES, V44, P1692, DOI 10.1194/jlr.M300041-JLR200
hcfmusp.relation.referenceRiddler SA, 2008, JAIDS-J ACQ IMM DEF, V48, P281, DOI 10.1097/QAI.0b013e31817bbbf0
hcfmusp.relation.referenceRose H, 2008, ATHEROSCLEROSIS, V199, P79, DOI 10.1016/j.atherosclerosis.2007.10.018
hcfmusp.relation.referenceSankatsing RR, 2009, ATHEROSCLEROSIS, V202, P589, DOI 10.1016/j.atherosclerosis.2008.05.028
hcfmusp.relation.referenceSHORPOSNER G, 1993, AM J MED, V94, P515, DOI 10.1016/0002-9343(93)90087-6
hcfmusp.relation.referenceStocker R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003
hcfmusp.relation.referenceSuzuki K, 2004, CANCER EPIDEM BIOMAR, V13, P1781
hcfmusp.relation.referenceTarr PE, 2010, PHARMACOGENOMICS, V11, P587, DOI [10.2217/pgs.10.35, 10.2217/PGS.10.35]
hcfmusp.relation.referenceTashima KT, 2003, HIV CLIN TRIALS, V4, P29
hcfmusp.relation.referenceThompson MA, 2010, JAMA-J AM MED ASSOC, V304, P321, DOI 10.1001/jama.2010.1004
hcfmusp.relation.referenceWang XW, 2007, JAIDS-J ACQ IMM DEF, V44, P493, DOI 10.1097/QAI.0b013e3180322542
hcfmusp.relation.referenceWohl D, 2008, JAIDS-J ACQ IMM DEF, V48, P44, DOI 10.1097/QAI.0b013e31816d9ba1
hcfmusp.remissive.sponsorshipCNPq
hcfmusp.remissive.sponsorshipFAPESP
hcfmusp.remissive.sponsorshipINCTs
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicationf29598ca-a95d-4013-8e99-2487b62b979b
relation.isAuthorOfPublication4437a063-fe85-4853-b700-f5dd69521c43
relation.isAuthorOfPublication34f28529-437f-4414-8216-701def73f655
relation.isAuthorOfPublication.latestForDiscoveryf29598ca-a95d-4013-8e99-2487b62b979b
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_MARANHAO_Serum_levels_of_IgG_antibodies_against_oxidized_LDL_2013.PDF
Tamanho:
3.01 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - ODS/03